Cetrorelix
Also known as: Cetrotide
Molecular Identifiers
Overview
GnRH receptor antagonist that competitively blocks LH and FSH release from the pituitary gland. Used in assisted reproduction protocols to prevent premature ovulation and in gonadal suppression research.
FDA-approved as Cetrotide for prevention of premature ovulation in controlled ovarian stimulation protocols for in vitro fertilization (IVF). Third-generation GnRH antagonist.
Ac-D-Nal-D-Cpa-D-Pal-Ser-Tyr-D-Cit-Leu-Arg-Pro-D-Ala-NH₂ Contains multiple D-amino acids and unnatural amino acids
Half-life
~62 hours
Administration Route
Subcutaneous
Category
Hormonal Regulation
Mechanism of Action
- Competitive antagonism of the GnRH receptor in the pituitary gland
- Rapid and reversible suppression of LH and FSH
- Prevention of premature LH surge
- Blockade of gonadotropin release without initial stimulation phase
- Dose-dependent effect on gonadal suppression
Dosage Protocol
Data compiled from the literature. This does not constitute medical advice.
| Parameter | Value |
|---|---|
| Dose | 0.25-3 mg per injection |
| Frequency | Once daily (0.25 mg) or single dose (3 mg) |
| Timing | As per hormonal protocol |
| Duration | Variable per protocol (usually 3-7 days in IVF) |
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Facial flushing
- Nausea
- Headache
- Injection site reactions
- Hot flashes
Presentations & Preparation
Vials of Cetrorelix found in the research market:
Reconstitution
- Diluent: Bacteriostatic water
- Volume: 1 ml per vial
- Slowly inject the diluent against the vial wall
- Gently swirl until fully dissolved
- Never shake
Storage
- Lyophilized: Refrigerated 2-8°C (may be stored at room temperature up to 25°C)
- Reconstituted: Use immediately after reconstitution
- Protect from direct light
- Use promptly after reconstitution
Related Peptides
Argipressin
5-20 IU or 1-4 mcg/kg · As clinically needed
Gonadorelin
100-200 mcg per injection · 2-3 times per week
HCG
250-500 IU per injection · 2-3 times per week
Kisspeptin-10
1-10 mcg per injection · Per research protocol
α-MSH
0.5-2 mg per injection · Once daily or every other day
Oxytocin
10-40 IU intranasal or 50-200 mcg subcutaneous · 1-2 times daily